194 related articles for article (PubMed ID: 32532738)
1. Application of Azamulin to Determine the Contribution of CYP3A4/5 to Drug Metabolic Clearance Using Human Hepatocytes.
Chanteux H; Rosa M; Delatour C; Nicolaï J; Gillent E; Dell'Aiera S; Ungell AL
Drug Metab Dispos; 2020 Sep; 48(9):778-787. PubMed ID: 32532738
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Erythromycin as a Tool to Assess CYP3A Contribution of Low Clearance Compounds in a Long-Term Hepatocyte Culture.
Chan TS; Scaringella YS; Raymond K; Taub ME
Drug Metab Dispos; 2020 Aug; 48(8):690-697. PubMed ID: 32503882
[TBL] [Abstract][Full Text] [Related]
3. Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible.
Stresser DM; Broudy MI; Ho T; Cargill CE; Blanchard AP; Sharma R; Dandeneau AA; Goodwin JJ; Turner SD; Erve JC; Patten CJ; Dehal SS; Crespi CL
Drug Metab Dispos; 2004 Jan; 32(1):105-12. PubMed ID: 14709627
[TBL] [Abstract][Full Text] [Related]
4. Reaction Phenotyping of Low-Turnover Compounds in Long-Term Hepatocyte Cultures Through Persistent Selective Inhibition of Cytochromes P450.
Smith S; Lyman M; Ma B; Tweedie D; Menzel K
Drug Metab Dispos; 2021 Nov; 49(11):995-1002. PubMed ID: 34407991
[TBL] [Abstract][Full Text] [Related]
5. Identification of human liver cytochrome P450 enzymes involved in biotransformation of vicriviroc, a CCR5 receptor antagonist.
Ghosal A; Ramanathan R; Yuan Y; Hapangama N; Chowdhury SK; Kishnani NS; Alton KB
Drug Metab Dispos; 2007 Dec; 35(12):2186-95. PubMed ID: 17827338
[TBL] [Abstract][Full Text] [Related]
6. Structural characterization of the homotropic cooperative binding of azamulin to human cytochrome P450 3A5.
Hsu MH; Johnson EF
J Biol Chem; 2022 May; 298(5):101909. PubMed ID: 35398097
[TBL] [Abstract][Full Text] [Related]
7. In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries.
Utkarsh D; Loretz C; Li AP
Chem Biol Interact; 2016 Aug; 255():12-22. PubMed ID: 26718876
[TBL] [Abstract][Full Text] [Related]
8. Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs.
Walsky RL; Obach RS; Hyland R; Kang P; Zhou S; West M; Geoghegan KF; Helal CJ; Walker GS; Goosen TC; Zientek MA
Drug Metab Dispos; 2012 Sep; 40(9):1686-97. PubMed ID: 22645092
[TBL] [Abstract][Full Text] [Related]
9. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.
Wang L; Zhang D; Raghavan N; Yao M; Ma L; Frost CE; Maxwell BD; Chen SY; He K; Goosen TC; Humphreys WG; Grossman SJ
Drug Metab Dispos; 2010 Mar; 38(3):448-58. PubMed ID: 19940026
[TBL] [Abstract][Full Text] [Related]
10. Estimation of Fraction Metabolized by Cytochrome P450 Enzymes Using Long-Term Cocultured Human Hepatocytes.
Klammers F; Goetschi A; Ekiciler A; Walter I; Parrott N; Fowler S; Umehara K
Drug Metab Dispos; 2022 May; 50(5):566-575. PubMed ID: 35246464
[TBL] [Abstract][Full Text] [Related]
11. Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation.
Bissada JE; Truong V; Abouda AA; Wines KJ; Crouch RD; Jackson KD
Drug Metab Dispos; 2019 Nov; 47(11):1257-1269. PubMed ID: 31492693
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes.
Lapham K; Callegari E; Cianfrogna J; Lin J; Niosi M; Orozco CC; Sharma R; Goosen TC
Drug Metab Dispos; 2020 Dec; 48(12):1350-1363. PubMed ID: 33020067
[TBL] [Abstract][Full Text] [Related]
13. VX-509 (Decernotinib)-Mediated CYP3A Time-Dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug Interactions.
Zetterberg C; Maltais F; Laitinen L; Liao S; Tsao H; Chakilam A; Hariparsad N
Drug Metab Dispos; 2016 Aug; 44(8):1286-95. PubMed ID: 27298338
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Disconnect between Hepatocyte and Microsome Intrinsic Clearance and In Vitro In Vivo Extrapolation Performance.
Williamson B; Harlfinger S; McGinnity DF
Drug Metab Dispos; 2020 Nov; 48(11):1137-1146. PubMed ID: 32847864
[TBL] [Abstract][Full Text] [Related]
15. Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4.
Zhang ZY; King BM; Pelletier RD; Wong YN
Cancer Chemother Pharmacol; 2008 Sep; 62(4):707-16. PubMed ID: 18431572
[TBL] [Abstract][Full Text] [Related]
16. Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide).
Tseng E; Walsky RL; Luzietti RA; Harris JJ; Kosa RE; Goosen TC; Zientek MA; Obach RS
Drug Metab Dispos; 2014 Jul; 42(7):1163-73. PubMed ID: 24737844
[TBL] [Abstract][Full Text] [Related]
17. Gomisin A is a Novel Isoform-Specific Probe for the Selective Sensing of Human Cytochrome P450 3A4 in Liver Microsomes and Living Cells.
Wu JJ; Ge GB; He YQ; Wang P; Dai ZR; Ning J; Hu LH; Yang L
AAPS J; 2016 Jan; 18(1):134-45. PubMed ID: 26361765
[TBL] [Abstract][Full Text] [Related]
18. Structural Insights into the Interaction of Cytochrome P450 3A4 with Suicide Substrates: Mibefradil, Azamulin and 6',7'-Dihydroxybergamottin.
Sevrioukova IF
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31480231
[TBL] [Abstract][Full Text] [Related]
19. In Vitro-In Vivo Inaccuracy: The CYP3A4 Anomaly.
Bowman CM; Benet LZ
Drug Metab Dispos; 2019 Dec; 47(12):1368-1371. PubMed ID: 31551322
[TBL] [Abstract][Full Text] [Related]
20. Development of Robust Quantitative Structure-Activity Relationship Models for CYP2C9, CYP2D6, and CYP3A4 Catalysis and Inhibition.
Gonzalez E; Jain S; Shah P; Torimoto-Katori N; Zakharov A; Nguyễn ÐT; Sakamuru S; Huang R; Xia M; Obach RS; Hop CECA; Simeonov A; Xu X
Drug Metab Dispos; 2021 Sep; 49(9):822-832. PubMed ID: 34183376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
